Zepbound Dosing, Ozempic Lawsuits, and What Patients Need to Know in 2025

Zepbound (tirzepatide) follows a specific dose-escalation schedule starting at 2.5 mg weekly and increasing every four weeks up to a maximum of 15 mg weekly. Meanwhile, Ozempic (semaglutide) is the subject of ongoing lawsuits alleging that its manufacturer, Novo Nordisk, failed to adequately warn patients about serious gastrointestinal side effects, including gastroparesis and intestinal obstruction. As a bariatric surgeon who has treated over 4,000 patients in my 20-plus year career, I want to give you a straightforward breakdown of both topics so you can make informed decisions about your weight loss treatment.

How Does Zepbound Dosing Work?

Zepbound is the brand name for tirzepatide when prescribed specifically for weight management. It is a dual GIP/GLP-1 receptor agonist, meaning it activates two gut hormone pathways instead of one. This dual mechanism is one reason why tirzepatide has shown greater average weight loss than semaglutide in clinical comparisons.

The FDA-approved dosing schedule for Zepbound is designed to minimize side effects, particularly nausea, by gradually increasing the dose over time:

• Weeks 1 through 4: 2.5 mg injected once weekly (this is a starting dose, not a therapeutic dose)
• Weeks 5 through 8: 5 mg once weekly
• Weeks 9 through 12: 7.5 mg once weekly
• Weeks 13 through 16: 10 mg once weekly
• Weeks 17 through 20: 12.5 mg once weekly
• Week 21 and beyond: 15 mg once weekly (maximum dose)

The dose escalation does not have to follow this exact timeline. Your prescribing physician may hold you at a particular dose longer if you are experiencing significant nausea, vomiting, or other side effects. In my practice, I frequently keep patients at a lower dose for an extra few weeks if they are tolerating it well and losing weight consistently. There is no rule that says you must reach 15 mg. Many patients achieve excellent results at 10 mg or even 7.5 mg.

What Weight Loss Can You Expect at Each Zepbound Dose?

The SURMOUNT-1 trial, published in the New England Journal of Medicine in 2022, showed that participants on the highest dose of tirzepatide (15 mg) lost an average of 22.5% of their body weight over 72 weeks. Those on the 10 mg dose lost about 21.4%, and those on 5 mg lost approximately 15%.

These are averages. Some patients lose substantially more, and some lose less. What I tell my patients is that GLP-1 medications are tools, not magic. They reduce appetite, slow gastric emptying, and help you feel satisfied with less food. But the actual weight loss depends heavily on what you eat and how active you are while taking the medication.

If you are losing weight steadily at 7.5 mg and tolerating it well, staying at that dose is perfectly reasonable. Pushing to a higher dose solely to speed things up often just increases side effects without a proportional increase in results.

Common Zepbound Side Effects and How to Manage Them

The most common side effects are gastrointestinal: nausea, diarrhea, constipation, decreased appetite, vomiting, and abdominal discomfort. These tend to be worst during dose escalations and typically improve within one to two weeks at each new dose level.

Here are some practical tips I share with patients:

• Eat smaller portions. The medication slows your stomach emptying. If you eat the same volume you ate before, you will feel overly full and nauseated.
• Avoid high-fat and greasy foods. Fat slows digestion further, compounding the effect.
• Stay hydrated. Sip water throughout the day. Dehydration worsens nausea and constipation.
• Time your injection wisely. Some patients find that injecting on a Friday evening gives them the weekend to manage any initial nausea before returning to work.

More serious side effects, including pancreatitis, gallbladder disease, and the gastrointestinal complications at the center of the Ozempic lawsuits, are less common but real. Any severe or persistent abdominal pain should prompt an immediate call to your doctor.

What Are the Ozempic Lawsuits About?

The Ozempic lawsuits (which also include Wegovy, since both contain semaglutide) are a growing area of litigation in 2025. Plaintiffs allege that Novo Nordisk knew or should have known about serious gastrointestinal risks and failed to provide adequate warnings to patients and healthcare providers.

The primary conditions cited in these lawsuits include:

• Gastroparesis (stomach paralysis): A condition where the stomach cannot empty food at a normal rate. Symptoms include severe nausea, vomiting, bloating, and abdominal pain. Some plaintiffs report that their gastroparesis persisted even after stopping the medication.
• Intestinal obstruction (bowel blockage): A potentially life-threatening condition requiring hospitalization and sometimes emergency surgery.
• Ileus: A condition where normal intestinal contractions stop temporarily, leading to a functional blockage.
• Severe vomiting leading to other complications: Including aspiration during anesthesia, which has prompted the American Society of Anesthesiologists to issue guidance about stopping GLP-1 medications before planned surgeries.

In August 2023, the FDA updated the Ozempic label to include a warning about intestinal obstruction. Many of the lawsuits argue that this warning came too late and was insufficient.

How Many Ozempic Lawsuits Have Been Filed?

As of early 2025, thousands of individual Ozempic lawsuits have been consolidated into multidistrict litigation (MDL) in the Eastern District of Pennsylvania under Judge Gene Pratter. The MDL, officially titled “In Re: Ozempic (Semaglutide) and Mounjaro (Tirzepatide) Products Liability Litigation,” also includes claims related to Mounjaro and Zepbound since tirzepatide works through similar mechanisms.

Bellwether trials, which are early test cases used to gauge how juries might respond, are expected to begin in 2025. The outcomes of these initial trials will likely influence whether Novo Nordisk and Eli Lilly pursue settlements or continue to fight the claims.

It is worth noting that Novo Nordisk has denied the allegations, maintaining that the risks of semaglutide are adequately disclosed in the drug’s labeling and that the benefits outweigh the risks for appropriate patients.

Should the Ozempic Lawsuit News Change Your Treatment Decision?

This is the question I get most often in clinic, and I want to give you a nuanced answer rather than a simple yes or no.

First, the existence of lawsuits does not prove that a medication is dangerous. Lawsuits are filed against virtually every widely prescribed medication. What matters is the actual incidence of serious side effects and how they compare to the risks of the condition being treated, which in this case is obesity.

Obesity significantly increases your risk of heart disease, type 2 diabetes, stroke, sleep apnea, certain cancers, and early death. GLP-1 medications like Ozempic and Zepbound have been shown to reduce many of these risks. The SELECT trial, published in 2023, demonstrated that semaglutide reduced major cardiovascular events by 20% in patients with obesity and established cardiovascular disease.

That said, the lawsuits raise legitimate concerns about whether certain patients are at higher risk for severe gastrointestinal complications and whether those patients should be screened more carefully before starting these medications. If you have a history of gastroparesis, prior bowel obstruction, or inflammatory bowel disease, these medications may carry higher risk for you, and that conversation needs to happen with your doctor before starting treatment.

My approach is straightforward: I discuss the known risks, the potential risks highlighted by the litigation, and the well-documented risks of untreated obesity. Then we make a decision together.

Are Zepbound and Mounjaro Included in the Lawsuits?

Yes. Although the litigation is commonly referred to as the “Ozempic lawsuit,” the MDL includes claims against Eli Lilly for Mounjaro and Zepbound (both tirzepatide) as well. The legal theory is essentially the same: that the manufacturer failed to adequately warn about serious gastrointestinal risks.

This is relevant to the Zepbound dosing discussion because higher doses of tirzepatide produce more pronounced effects on gastric motility. In theory, the risk of gastroparesis and related conditions may be dose-dependent, though this has not been definitively established in clinical studies.

This is another reason why I advocate for using the lowest effective dose rather than automatically escalating to the maximum.

GLP-1 Medications vs. Bariatric Surgery: How Do They Compare?

As someone who performs bariatric surgery regularly and also prescribes GLP-1 medications, I see the strengths and limitations of both approaches.

GLP-1 medications typically produce 15 to 25% total body weight loss, depending on the specific drug and dose. Bariatric surgery produces 25 to 35% weight loss on average, with some procedures like the duodenal switch producing even more. Surgery also has longer-term data supporting durability of weight loss and resolution of conditions like type 2 diabetes.

The major limitation of GLP-1 medications is that weight regain after stopping the drug is common and substantial. The STEP-1 trial extension showed that participants regained two-thirds of their lost weight within one year of discontinuing semaglutide. This means most patients will need to take these medications indefinitely to maintain their results.

Surgery, on the other hand, creates permanent anatomical changes that support long-term weight maintenance without ongoing medication in many cases.

For patients with BMI over 40, or BMI over 35 with obesity-related health conditions, I still believe bariatric surgery offers the most reliable and durable outcome. GLP-1 medications are an excellent option for patients who do not qualify for surgery, prefer a non-surgical approach, or need additional support after surgery.

What Should You Do If You Are Currently Taking Ozempic or Zepbound?

Do not stop your medication because of lawsuit headlines. Abruptly discontinuing GLP-1 medications can lead to rapid weight regain and metabolic destabilization, particularly if you have type 2 diabetes.

Instead, take these practical steps:

• Report any severe or unusual gastrointestinal symptoms to your prescribing doctor immediately. Persistent vomiting, severe abdominal pain, inability to eat, or signs of dehydration all warrant prompt medical attention.
• Inform your surgeon and anesthesiologist if you are scheduled for any procedure. Current recommendations suggest holding GLP-1 medications for at least one week (and possibly longer for weekly formulations) before elective surgery to reduce aspiration risk.
• Keep records of your side effects. Document dates, symptoms, and any communication with your healthcare provider. This is good practice regardless of the legal situation.
• Have an honest conversation with your doctor about your individual risk profile. Not every patient on these medications faces the same level of risk.

Moving Forward with the Right Information

The weight loss medication field is evolving quickly. New drugs, new data, and yes, new legal developments are emerging regularly. What does not change is the basic principle that every treatment decision should weigh the benefits against the risks for you specifically, not for the average patient in a clinical trial and not based on headlines.

If you are considering Zepbound, Ozempic, or any other GLP-1 medication, or if you want to understand how these medications compare to surgical options, I recommend scheduling a consultation with a physician who has expertise in obesity medicine. With over 20 years of experience treating obesity both surgically and medically, I can tell you that the best outcomes come from individualized treatment plans, not one-size-fits-all prescriptions.